Intermittent vismodegib therapy in basal cell nevus syndrome

JAMA Dermatology

Volumn 152, Issue 2, 2016, Pages 223-224

  Yang, Xinyi ^a   Dinehart, Scott M ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Arkansas Skin Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANILIDE; ANTINEOPLASTIC AGENT; PYRIDINE DERIVATIVE; VISMODEGIB;

ADULT; AGONISTS; BASAL CELL NEVUS SYNDROME; CASE REPORT; DRUG ADMINISTRATION; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; SKIN NEOPLASMS; TREATMENT OUTCOME;

ADULT; ANILIDES; ANTINEOPLASTIC AGENTS; BASAL CELL NEVUS SYNDROME; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRIDINES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84957968793     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2015.3210     Document Type: Letter

References (6)

1. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366 (23):2180-2188.
2. Ally MS, Tang JY, Joseph T, et al. The use of vismodegib to shrink keratocystic odontogenic tumors in patients with basal cell nevus syndrome. JAMA Dermatol. 2014;150(5):542-545.
3. Lorusso PM, Jimeno A, Dy G, et al. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(17): 5774-5782.
4. Chang ALS, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch Dermatol. 2012;148(11):1324-1325.
5. Kim J, Aftab BT, Tang JY, et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 2013;23(1):23-34.
6. Long J, Li B, Rodriguez-Blanco J, et al. The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers. J Biol Chem. 2014;289(51):35494-35502.